Compare Gartner Inc (IT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs TG Therapeutics Inc — how do they compare? Gartner Inc trades at $191.18 (market cap $12.34B), while TG Therapeutics Inc trades at $55.11 (market cap $8.16B). The key difference: Gartner Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gartner Inc for 64 Days and TG Therapeutics Inc for 16 Days on average.
| IT | TGTX | |
|---|---|---|
Market Cap | $12.34B | $8.16B |
Volume | 919,809 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $258.17 | $59.06 |
52-Week Low | $125.68 | $26.94 |
Typical Hold Time | 64 Days | 16 Days |
Enterprise Value | $14.08B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner (IT) trades at $191.02, up 2.83% with a bullish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Financials show strong profitability with a 69.63% gross margin and 113.58% ROE, though net income declined in 2025. Recent news highlights AI advisory demand and Gartner's industry leadership, driving positive sentiment.
Outlook remains supported by robust contract value and AI-driven consulting growth, but risks include a high P/B ratio of 160.06 and a shareholder investigation. Analyst consensus is mixed with a $174.63 price target below the current price, suggesting caution despite bullish technicals.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
